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OBJECTIVES The purpose of this study was to compare two different intensities of vitamin K antagonists
(VKA) among patients with mechanical heart valves using meta-analytic techniques.
BACKGROUND Patients with mechanical heart valves are at increased risk for valve thrombosis and systemic
embolism, which can be reduced by VKA. The range of optimal intensity of VKA is still a
matter of debate.
METHODS A computerized search in the PubMed database was made for relevant articles. A
meta-analysis was performed of all eligible studies with data on the incidences of thrombo-
embolic and bleeding complications in patients with mechanical heart valve prostheses during
different intensities of VKA therapy. The studies were classified into low-intensity VKA
therapy (mean target international normalized ratio [INR] of 3.0 or lower) or high-intensity
VKA therapy (mean target INR above 3.0).
RESULTS Thirty-five eligible studies were identified, including in total 23,145 patients, who were
studied for 108,792 patient-years. For patients with an aortic valve, high intensity resulted in
a lower incidence of thromboembolic events (risk ratio [RR]  0.73, p  0.0001); however,
the incidence of bleeding was increased (RR  1.23, p  0.0001). In the mitral valve group,
the incidence rate for thromboembolism was lower in the high-intensity group (RR  0.74,
p  0.0001), without a significantly increased bleeding incidence (RR  1.08, p  0.0524).
The total number of thromboembolic and bleeding events was decreased in the high-intensity
group compared with low-intensity VKA therapy for both aortic and mitral valve prostheses
(RR  0.94 [p  0.0067] and 0.84 [p  0.0001]), respectively.
CONCLUSIONS This meta-analysis shows that both aortic and mitral valves will benefit from a treatment
strategy with a target INR higher than 3.0. (J Am Coll Cardiol 2003;42:2042–8) © 2003
by the American College of Cardiology Foundation
Patients with mechanical heart valves are at increased risk
for valve thrombosis and systemic embolism, predominantly
stroke. The incidence rates of these serious complications
can be reduced by vitamin K antagonist (VKA) therapy, and
life-long anticoagulation is recommended in patients with
mechanical heart valves. However, life-long anticoagulant
therapy is associated with a risk of severe and sometimes
fatal bleeding. The relationship between preventing throm-
boembolism and introducing bleeding complications is rep-
resented by a U-shaped relationship between the intensity
of VKA and the risk of thromboembolic and bleeding
events. Therefore, the optimal VKA intensity defined as the
intensity at which the incidence of both thromboembolic as
well as bleeding complications is lowest, is a delicate
equilibrium. The first American College of Chest Physi-
cians guidelines published in 1986 recommended an inter-
national normalized ratio (INR) between 3.0 and 4.5,
regardless of the position of the valve (1,2). In 1995
Cannegieter et al. (3) described, on the basis of a discrep-
ancy between targeted and achieved INR, the relationship
between the effectiveness of anticoagulation and the actually
achieved intensities. The study showed that the optimal
intensity of anticoagulation, resulting in the fewest adverse
events, lies between INR levels of 2.5 and 4.9. The
incidence of the events rises sharply above or below this
range. As a target range, they recommended an INR of 3.0
to 4.0 for both aortic and mitral valves, although it was
shown that the risk of thromboembolic complications ap-
pears to vary with the position of the valve. Patients with a
prosthesis in the mitral position have a significantly higher
risk of thromboembolic complications than those with an
aortic valve prosthesis (4). Based on this discrepancy, more
recently, a minor discrimination in anticoagulation intensity
was recommended between aortic and mitral valves, and the
target range was lowered to 2.0 and 3.5 (5), depending on
the position and type of the valve. However, these latest
guidelines are based on only a few studies. Thus, the range
of optimal intensity of VKA is an ongoing matter of debate,
moreover because it is difficult to assess the individual risk of
thromboembolism and bleeding in an individual patient. To
obtain reliable estimates on the adverse events and to
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formulate guidelines for daily clinical practice, we per-
formed an extended analysis of all published studies with
data on the incidence of thromboembolic and bleeding
events in patients with a mechanical heart valve in either the
aortic or the mitral position during different intensities of
VKA therapy.
METHODS
Selection of articles. A computerized search in the
PubMed database over the period January 1965 to June
2002 was performed to retrieve studies with data on the
incidences of thromboembolic and bleeding complications
in patients with mechanical heart valve prostheses. The key
words used were: heart valve prosthesis, mechanical heart
valve, anticoagulants, coumarin, warfarin, thromboembo-
lism, and hemorrhage. Subsequently, a manual search of the
reference lists from the retrieved articles was done to
identify additional articles. Only studies that met the
following criteria were included: 1) the possibility to differ-
entiate between aortic valve prosthesis and mitral valve
prosthesis; 2) specification of the target INR or prothrom-
bin time of VKA therapy; 3) no change in the target INR or
prothrombin time ratio during follow-up; 4) thromboem-
bolic and bleeding events classified according to Edmunds
et al. (6) or otherwise adequately classified; and 5) mean age
of the patients older than 18 years. Studies were excluded
when: 1) the number of patients lost to follow-up was larger
than 5%; 2) the study included bioprostheses or caged-ball
valves; 3) the patients received antiplatelet therapy alone or
antiplatelet therapy in combination with VKA; and 4) the
cohort was the same as reported in another included study.
Data extraction. All potentially eligible articles were eval-
uated independently by two reviewers. Data on the position
and type of the prosthetic valve, target INR or prothrombin
time ratio, number of patients, and patient-years were
extracted from each study. The outcome events of interest
included valve thrombosis, systemic embolism, and bleed-
ing. A data form was used to collect this information.
Disagreements were resolved by consensus.
Outcome events. The events were analyzed according to
the guidelines for reporting morbidity and mortality after
cardiac valvular operations of Edmunds et al. (6). Briefly,
thromboembolic events included all neurologic and periph-
eral embolic events. A neurologic event includes any new,
temporary, or permanent focal or global neurologic deficit.
A peripheral embolic event is an operative, autopsy-proven
or clinically documented embolus that produces symptoms
from complete or partial obstruction of a peripheral artery.
Valve thrombosis is any thrombus, in the absence of
infection, that occludes (part of) the transvalvular blood flow
and/or that interferes with the function of the valve. Valve
thrombosis may be documented by operation, autopsy, or
clinical investigation (e.g., echocardiography, angiocardio-
graphy, or magnetic resonance imaging). A bleeding event is
defined as any episode of major internal or external bleeding
that causes death, hospitalization, permanent injury, or
requires transfusion.
Subgroups. We separately analyzed studies with aortic and
mitral valve prostheses. These studies were subdivided into
low- or high-intensity VKA therapy. Low-intensity VKA
therapy was defined as a mean target INR of 3.0 or lower.
High-intensity was defined as a mean target INR above 3.0.
The results of the thrombotest and prothrombin time ratios
were converted to INR, using the international sensitivity
index of the prothrombin time assays as reported by the
authors or requested from them.
Statistical analysis. For each outcome event and per study
separately, an annual incidence (number of outcome events
divided by the number of patient-years) and its standard
error were calculated. In case the number of events was 0, a
statistical correction for the standard error was made by
adding a fictive number of 0.5 events to the number of
events and to the number of patient-years. The significant
chi-square test for each outcome result may implicate
heterogeneity between the studies. Therefore, we did not
use the fixed effect method, but the random effect method.
Because study size would have small effect in a random effect
model, the calculated incidences were averaged by adding
the yearly incidence rates of all studies divided by the
number of studies. The 95% confidence intervals (CI) of
rate ratios were calculated with the assumption of a Poisson
distribution. Statistical significance between the incidences
of two groups was calculated using the Wald test. A value of
p  0.05 (two-sided) was considered to be statistically
significant.
RESULTS
Studies. The literature search identified 141 potentially
eligible articles. Of these 141 articles, 35 could be included
in the analysis. Reasons for exclusion were as follows:
inability to differentiate between aortic and mitral valves (23
studies); intensity of oral anticoagulant therapy was not
specified (27 studies); the use of antiplatelet therapy (14
studies); the events or patient-years were not specified (18
studies); the cohort was the same as another included study
(8 studies); lost to follow-up not specified or exceeding 5%
(6 studies); or other reasons (10 studies). The list of
excluded articles will appear in the online Appendix for this
article (www.cardiosource.com/jacc.html).
Not all of the outcome events were reported in all of the
studies. Of the 35 studies, 26 were eligible for analysis of both
aortic and mitral valve prostheses (7–32). Four studies only
reported on aortic valve prostheses (33–36), and five other
Abbreviations and Acronyms
CI  confidence interval
INR  international normalized ratio
RR  risk ratio
VKA  vitamin K antagonists
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reports concerned mitral valve prostheses only (37–41). The 35
studies included 23,145 patients with a total of 108,792
patient-years. For the aortic valve prostheses group, 13,337
patients were followed for 63,432 patient-years, and 9,808
patients in the mitral valve prostheses group were followed for
45,360 patient-years. In the high-intensity VKA group, the
highest observed upper limit of the INR was 4.8.
In Tables 1 and 2, the results of the separate studies are
given, divided in four subgroups, namely, patients with
prosthetic aortic valves or prosthetic mitral valves with
either high- or low-intensity VKA therapy.
High- versus low-intensity VKA therapy in patients with
aortic valve prostheses. The incidence rates of valve
thrombosis, thromboembolism, and bleeding for high- and
low-intensity VKA therapy in patients with an aortic valve
prosthesis are shown in Table 3, expressed as number of
events per 1,000 patient-years. With high-intensity VKA
therapy (mean target INR above 3.0), the incidence of valve
thrombosis was 0.87 per 1,000 patient-years and the inci-
dence of embolism was 9.83 per 1,000 patient-years com-
pared with 1.16 events per 1,000 patient-years and 13.09
per 1,000 patient-years for the low-intensity group (mean
target INR below 3.0), with risk ratios (RR) of 0.75, 95%
CI 0.50 to 1.13 and 0.75, 95% CI 0.70 to 0.81, respectively.
The total number of thromboembolic events (a combination
of valve thrombosis and embolism together) was 10.01 per
1,000 patient-years for the high-intensity group and 13.69
per 1,000 patient-years for the low-intensity group (RR 
0.73, 95% CI 0.68 to 0.78). There was an increase in the
incidence of bleeding events in the high-intensity group
compared with low-intensity VKA therapy (14.89 vs. 12.06
per 1,000 patient-years; RR  1.23, 95% CI 1.16 to 1.31).
The total number of events, that is, all thromboembolic and
bleeding events, in the high-intensity group was 23.84 per
1,000 patient-years; in the low-intensity group 25.39 events
per 1,000 patient-years. This is a decrease of events with a
significant RR of 0.94 (95% CI 0.88 to 0.99).
High- versus low-intensity VKA therapy in patients with
mitral valve prostheses. The results of the analysis in the
group of patients with a prosthetic mitral valve are listed in
Table 4. Patients who received high-intensity VKA therapy
had a lower risk for valve thrombosis and systemic emboli-
Table 1. Overview of Studies Used for the Analysis of Mechanical Aortic Valves
Author (Ref.) Valve Type Pt-Yrs VT* TE* VTTE* Hemor* All* Age % Male
High-intensity aortic valve
Aris et al. 1996 (7) MS 12,929 0.08 8.74 8.82 8.97 17.79 53 52
Nitter-Hauge et al. 1996 (8) MH 7,611 0.53 18.00 18.53 ns ns 56 69
Milano et al. 1992 (9) SO 1,650 0.61 12.12 12.73 9.09 21.82 48 78
Peter et al. 1993 (10) OC 269 1.86 7.43 7.43 11.15 18.59 61 67
Obadia et al. 1997 (33) MH 884 0.57 5.66 5.66 30.54 36.20 63 82
Podesser et al. 1998 (11) ED 1,978 ns ns 8.59 16.68 25.28 55 64
Debetaz et al. 1997 (12) SJ 1,750 1.71 20.00 21.71 33.14 54.86 58 32
Aagaard et al. 1995 (13) CM 647 0.77 3.09 3.09 7.73 10.82 57 61
Sethia et al. 1986 (14) BS 1,121 ns 3.57 3.57 1.78 5.35 50 ns
Total 28,839 0.87 9.83 10.01 14.89 23.84 56 58
Low-intensity aortic valve
Kim et al. 1994 (15) MH/MS 1,045 ns 8.61 8.61 ns ns 55 52
Torregrosa et al. 1999 (16) OC 970 0.52 1.03 1.03 10.31 11.34 54 75
Borman et al. 1998 (17) SO 1,593 0.63 11.30 11.93 12.55 24.48 58 60
Akins et al. 1996 (18) MH 765 0.65 13.07 13.07 16.99 30.07 57 76
Goldsmith et al. 1999 (19) SO 505 0.99 27.72 27.72 23.76 51.49 58 56
Bortolotti et al. 2001 (20) SO 1,703 0.59 13.51 14.09 13.51 27.60 60 72
Smith et al. 1993 (21) SJ 1,640 0.30 6.10 6.10 9.76 15.85 54 72
Dalrymple-Hay et al. 2000 (22) CM 2,495 0.40 16.43 16.83 16.43 33.27 63 68
Ismeno et al. 2001 (34) SJ 512 0.98 3.91 3.91 1.95 5.86 64 34
Nistal et al. 1996 (23) CM 522 0.96 30.65 30.65 19.16 49.81 54 74
Baudet et al. 1995 (24) SJ 6,419 2.49 8.41 10.91 9.50 20.41 57 69
Khan et al. 2001 (25) SJ 3,881 3.09 24.99 28.09 20.10 48.18 65 51
Thevenet et al. 1995 (26) OC 760 0.66 1.32 1.32 6.58 7.89 58 57
Nakano et al. 1994 (27) SJ 1,919 0.52 13.03 13.55 1.04 14.59 48 67
Fiane et al. 1998 (28) CM 3,176 0.31 8.82 9.13 6.93 16.06 62 57
Lund et al. 1990 (35) SJ 296 1.69 13.51 13.51 ns ns 60 53
Zellner et al. 1999 (29) SJ 2,376 2.95 20.20 23.15 26.94 50.08 55 70
Olesen et al. 1991 (36) LK 2,301 0.87 13.47 15.21 6.52 21.73 53 73
Otaki et al. 1993 (30) OC 166 3.01 3.01 3.01 3.01 3.01 49 47
Damle et al. 1987 (32) OS 454 1.10 22.03 22.03 ns ns 51 70
Arom et al. 1987 (31) SJ 1,095 0.46 13.70 13.70 ns ns ns ns
Total 34,593 1.16 13.09 13.69 12.06 25.39 57 64
*Expressed as number of events per 1,000 patient-years.
Age  mean age at valve implantation; All  all thromboembolic and bleeding events; BS  Bjo¨rk-Shiley; CM  Carbomedics; ED  Edwards Duromedics; Hemor 
hemorrhage; LK  Lillehei-Kaster; MH  Medtronic Hall; MS  Monostrut; ns  not specified; OC  Omnicarbon; OS  Omniscience; Pt-yrs  patient-years; SJ  St.
Jude; SO  Sorin; TE  thromboembolism; VT  valve thrombosis; VTTE  all valve thrombosis or thromboembolism.
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zation than those receiving low-dose VKA, with a RR of
0.60 (95% CI 0.47 to 0.76) and 0.79 (95% CI 0.74 to 0.84),
respectively. The occurrence of bleeding complications did
not differ with the use of high-dose VKA compared with
low-dose VKA (12.94 vs. 11.96 events per 1,000 patient-
years; RR  1.08, 95% CI 1.00 to 1.16, p  0.0524). The
total number of events (thromboembolic and bleeding
events) was 29.76 per 1,000 patient-years in the high-
intensity VKA group and 35.33 per 1,000 patient-years in
the low-intensity VKA group (RR 0.84, 95% CI 0.79 to
0.89).
Aortic versus mitral valve prostheses. The number of
valve thrombosis and thromboembolic events is significantly
lower in the aortic valve group compared with the mitral
valve group for both low- and high-intensity VKA therapy.
The RRs are shown in Table 5. Treatment with high-
intensity therapy significantly increased bleeding events in
patients with a prosthetic aortic valve compared with pa-
tients with a mitral valve (RR 1.15, 95% CI 1.06 to 1.25).
No difference in bleeding complications was observed be-
tween patients with aortic and mitral valves treated with
low-intensity VKA (RR  1.01, 95% CI 0.94 to 1.07). The
Table 2. Overview of Studies Used for the Analysis of Mechanical Mitral Valves
Author (Ref.) Valve Type Pt-Yrs VT* TE* VTTE* Hemor* All* Age % Male
High-intensity mitral valve
Aris et al. 1996 (7) MS 11,549 0.35 17.14 17.49 10.39 27.88 53 52
Nitter-Hauge et al. 1996 (8) MH 1,632 1.84 19.00 20.83 ns ns 56 69
Milano et al. 1992 (9) SO 963 1.04 12.46 13.50 9.35 22.85 48 33
Remadi et al. 2001 (37) SJ 4,877 2.05 6.97 9.02 9.84 18.86 60 46
Dalrymple-Hay et al. 2000 (22) CM 1,096 0.46 14.60 14.60 22.81 37.41 65 44
Jegaden et al. 1994 (38) SJ 1,334 ns ns 20.99 9.00 29.99 55 ns
Goldsmith et al. 1999 (19) SO 316 1.58 9.49 9.49 22.15 31.65 61 56
Borman et al. 1998 (17) SO 1,120 5.36 21.43 26.79 6.25 33.04 58 60
Peter et al. 1993 (10) OC 117 4.27 17.09 17.09 8.55 25.64 61 67
Debetaz et al. 1997 (12) SJ 1,000 0.50 29.00 29.00 34.00 63.00 57 44
Podesser et al. 1998 (11) ED 1,286 ns ns 11.66 10.89 22.55 53 50
Thevenet et al. 1995 (26) OC 444 2.25 9.01 11.26 11.26 22.52 58 57
Aagaard et al. 1995 (13) CM 333 3.00 18.02 21.02 12.01 33.03 54 38
Sethia et al. 1986 (14) BS 1,788 ns 16.78 16.78 1.68 18.46 50 ns
Total 27,855 2.06 15.91 17.11 12.94 29.76 56 51
Low-intensity mitral valve
Kim et al. 1994 (15) MH/MS 708 ns 18.36 18.36 ns ns 55 52
Hayashi et al. 1994 (39) SJ 845 ns 15.38 15.38 ns ns 49 41
Torregrosa et al. 1999 (16) OC 1,210 2.48 6.61 9.09 7.44 16.53 54 35
Akins et al. 1996 (18) MH 481 2.08 20.79 22.87 18.71 41.58 62 27
Bortolotti et al. 2001 (20) SO 1,021 2.94 18.61 21.55 10.77 32.32 58 37
Camilleri et al. 2001 (40) SO/SJ 396 7.58 12.63 20.20 10.10 30.30 58 49
Nistal et al. 1996 (23) CM 431 4.64 37.12 41.76 27.84 69.61 55 34
Baudet et al. 1995 (24) SJ 1,580 4.43 17.72 22.15 8.86 31.01 53 46
Khan et al. 2001 (25) SJ 2,662 2.25 28.93 31.18 19.16 50.34 65 51
Nakano et al. 1994 (27) SJ 3,318 0.90 15.97 16.88 1.81 18.69 48 39
Fiane et al. 1998 (28) CM 677 4.43 10.34 14.77 2.95 17.73 62 57
Zellner et al. 1999 (29) SJ 1,868 0.54 33.73 34.26 15.52 49.79 52 38
Damle et al. 1987 (32) OS 547 1.83 21.94 23.77 ns ns 51 35
Arom et al. 1987 (31) SJ 778 3.86 25.71 29.56 ns ns ns ns
Fiore et al. 1998 (41) MH/SJ 789 5.07 32.95 38.02 17.74 55.77 60 38
Otaki et al. 1993 (30) OC 194 5.15 5.15 10.31 2.58 10.31 49 47
Total 17,505 3.44 20.12 23.13 11.96 35.33 55 42
*Expressed as number of events per 1,000 patient-years.
Abbreviations as in Table 1.
Table 3. Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With
Mechanical Aortic Valve, According to Vitamin K Antagonist Intensity
Events/1,000 Pt-Yrs
Risk Ratio 95% CI p ValueAortic Valve High Aortic Valve Low
VT 0.87 1.16 0.75 0.50–1.13 0.1260
TE 9.83 13.09 0.75 0.70–0.81 0.0001
VTTE 10.01 13.69 0.73 0.68–0.78 0.0001
Hemor 14.89 12.06 1.23 1.16–1.31 0.0001
All 23.84 25.39 0.94 0.88–0.99 0.0067
CI  confidence interval; other abbreviations as in Table 1.
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total number of events (thromboembolism and bleeding) for
both high- and low-intensity treatment was lower in the
aortic valve group than for patients in the mitral valve group
(RR 0.80, 95% CI 0.75 to 0.85, and RR 0.72, 95% CI 0.68
to 0.76, respectively).
DISCUSSION
Anticoagulant therapy with VKA for patients with a me-
chanical heart valve has been the subject of intense debate.
Since 1992, the target range of the INR has been lowered
from INR values between 3.0 and 4.5 to less intensive
values, that is, between 2.0 and 3.5. Furthermore, because
aortic valve prostheses are considered less thrombogenic
than prostheses in the mitral position, a target INR at the
lower side of this range is advised for aortic valves, whereas
a target INR at the upper side of this range is suggested for
mitral valves (5). Nevertheless, the present literature review
shows that patients with a mechanical heart valve in the
aortic as well as in the mitral position will benefit from
high-intensity VKA treatment. The number of thrombo-
embolic events is lowest for both the aortic and the mitral
valve group with the strategy of this high target INR. The
total number of thromboembolic and bleeding events, the
most important parameter for the efficacy of treatment, is
significantly decreased when patients are treated with high-
intensity VKA therapy compared with low-intensity VKA
therapy.
Although the decrease in thromboembolic events is
similar for both aortic and mitral valves (RR  0.73 and
0.74), it was shown that in patients with a mechanical aortic
valve treated with high-intensity VKA therapy significantly
more bleeding episodes occurred compared with those
treated with low-intensity VKA. A nonsignificant trend
toward a higher frequency of bleeding events with high-
intensity VKA was observed in the mitral valve group of our
study. Therefore, because the strong correlation between the
intensity of VKA and the risk of bleeding events is a
well-established fact (3,42,43), this high-intensity strategy
is relatively more effective for mitral valve prostheses than
for aortic valve prostheses (RRs for total number of events
0.84 and 0.94, respectively).
Patients with a mechanical heart valve in the aortic
position have an increased risk for bleeding complications
compared with patients with a mechanical mitral valve. This
risk is significantly increased at high levels of VKA therapy.
The number of bleeding events is 14.89 per 1,000 patient-
years in the aortic valve group versus 12.94 events per 1,000
patient-years in the mitral valve group (RR 1.15, 95% CI
1.06 to 1.25). A possible mechanism for this observation is
that the two patient groups have a different bleeding risk
profile. Hypertension and atherosclerosis may result in a
slightly increased bleeding risk (44,45). These cardiovascu-
lar risk factors are frequent among patients with aortic
stenosis, which is the main indication for aortic valve
replacement. Another possibility may be that patients with
an aortic prosthesis are in a general better condition and
may lead a more active life, thereby somewhat increasing the
risk of bleeding.
The incidence of valve thrombosis and thromboembolism
is higher in patients with mitral valve prostheses than with
aortic valve prostheses for both low- and high-intensity
VKA therapy. This is presumably due to different blood
flow properties over the mitral valve compared with the
aortic valve and the relatively increased incidence of atrial
fibrillation in patients with mitral valve heart disease.
There are a few limitations of the present study. First,
most reports used for this analysis are based on an intention
to treat INR range and, therefore, information on the
actually achieved intensity of VKA treatment and the
compliance of therapy was lacking. The time spent in the
therapeutic range is approximately 50% to 70% in well-
designed cohorts (46), and it is unlikely that the achieved
Table 4. Incidence Rates of Thromboembolic and Hemorrhagic Complications in Patients With
Mechanical Mitral Valve, According to Vitamin K Antagonist Intensity
Events/1,000 Pt-Yrs
Risk Ratio 95% CI p ValueMitral Valve High Mitral Valve Low
VT 2.06 3.44 0.60 0.47–0.76 0.0001
TE 15.91 20.12 0.79 0.74–0.84 0.0001
VTTE 17.11 23.13 0.74 0.70–0.78 0.0001
Hemor 12.94 11.96 1.08 1.00–1.16 0.0524
All 29.76 35.33 0.84 0.79–0.89 0.0001
Abbreviations as in Tables 1 and 3.
Table 5. Risk Ratios of Thromboembolic and Hemorrhagic
Events for Patients With a Mechanical Aortic Valve Compared
With Mechanical Mitral Valve
Aortic vs.
Mitral Valve Event
Risk Ratio
Aortic vs.
Mitral 95% CI
p
Value
High intensity VT 0.42 0.27–0.66 0.0001
TE 0.62 0.56–0.68 0.0001
VTTE 0.59 0.54–0.63 0.0001
Hemor 1.15 1.06–1.25 0.0014
All 0.80 0.75–0.85 0.0001
Low intensity VT 0.34 0.29–0.39 0.0001
TE 0.65 0.62–0.68 0.0001
VTTE 0.59 0.57–0.62 0.0001
Hemor 1.01 0.94–1.07 0.8026
All 0.72 0.68–0.76 0.0001
Abbreviations as in Tables 1 and 3.
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INR range in our study population will exceed this percent-
age. Because most of the adverse events occur in the period
of under- or over-coagulation, it is plausible to assume that
the risk for embolism and bleeding will decrease with a
more stable level of anticoagulation. In addition, a major
effect of anticoagulation control on the long-term survival
was shown in a recent study (47), demonstrating that a high
variability in INR was the strongest independent predictor
of reduced survival. In this report, there was a 32% differ-
ence in survival at 15 years between patients with low and
high variability in anticoagulation control. This observation
emphasizes the importance of adequate management of
anticoagulation. Several developments in therapeutic quality
control have improved the safety and efficacy of VKA
therapy. Monitoring of VKA therapy by a specialized
anticoagulation clinic reduces the bleeding and thrombo-
embolic event rates (48). More recently, home testing of the
intensity of anticoagulation by means of a portable coagu-
lometer that performs an INR on a single drop of capillary
blood has become available. The INR home testing appears
to be a safe and efficient anticoagulation control method
which results in a higher percentage of target range values
compared with the conventional laboratory-based testing
regimen (49–51).
A second limitation may be that most of the included
studies were cohort series, without a control group. These
cohort studies, however, allow for the estimate of the
absolute risk of bleeding and thrombosis. This pooled
analysis of 35 studies, with in total more than 23,000
patients who were followed for more than 100,000 patient-
years, indeed yielded sufficient power to detect significant
differences in favor of high-intensity VKA therapy. To
minimize the risk for bias, we only selected studies wherein
all the adverse events were classified according to an
internationally accepted scoring system.
Another limitation is that some studies used older valve
types. However, most valve types used in the analysis are
still being used for insertion nowadays.
Total mortality would be an important outcome in this
analysis. Unfortunately, from the majority of the studies
used for the analysis, no data on mortality could be retrieved
to allow estimation of a reliable mortality rate.
Our recommendations are based on data derived from
patients with a mean age at valve implantation of 55 years.
Because there is a trend towards valve replacements in older
age groups and because older patients have an increased
bleeding risk (3), it is uncertain whether this group of
patients will benefit from high-intensity VKA therapy.
However, in our analysis we were not able to identify
age-associated risks, because most of the studies only report
on age as a baseline characteristic.
The role of antiplatelet therapy in patient with mechan-
ical heart valves remains controversial. Two recent random-
ized trials evaluated the effects of adding aspirin to VKA
treatment. Turpie et al. (52) showed that aspirin (100
mg/day) in combination with VKA (INR 3.0 to 4.5) was
associated with fewer thromboembolic events than VKA
alone, although the rate of major bleeding was increased.
Meschengieser et al. (53) demonstrated in their trial that
aspirin (100 mg/day) in combination with VKA (INR 2.5 to
3.5) was as effective as VKA (INR 3.5 to 4.5) alone. The
results from these studies cannot be considered as sufficient
evidence for recommending combination therapy. In excep-
tional cases of patients with thromboembolic complications
despite adequate VKA therapy, the addition of antiplatelet
therapy can be considered for the prevention of thrombo-
embolic events.
In conclusion, this analysis shows that both patients with
aortic and mitral valve will benefit from high-intensity VKA
therapy, with a target INR above 3.0. For daily practice, we
recommend an INR between 3.0 and 4.5. Because aortic
valve prostheses are considered less thrombogenic than
prostheses in the mitral position, a target INR at the lower
side of this range is advised for aortic valves, whereas a target
INR at the upper side of this range is suggested for mitral
valves. However, a prospective study that addresses both the
intensity of VKA and the position of the mechanical heart
valve is definitely needed before the discussion can be
resolved.
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APPENDIX
For the list of excluded articles, please see the December 17,
2003, issue of JACC at www.cardiosource.com/jacc.html.
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